



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : G01N 33/543, 21/75</p>	A1	<p>(11) International Publication Number: WO 90/11525</p> <p>(43) International Publication Date: 4 October 1990 (04.10.90)</p>
<p>(21) International Application Number: PCT/GB90/00433</p> <p>(22) International Filing Date: 21 March 1990 (21.03.90)</p> <p>(30) Priority data: 8906776.3 23 March 1989 (23.03.89) GB</p> <p>(71) Applicant (for all designated States except US): AMERSHAM INTERNATIONAL PLC [GB/GB]; Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : CHARLES, Stephen, Alexander [GB/GB]; 5 Eliot Close, Heydon Hill, Aylesbury, Bucks. HP1 9JB (GB). FINLAN, Martin, Francis [GB/GB]; 7 Ballard Close, Aylesbury, Bucks. HP21 9YU (GB). GARLAND, Peter, Bryan [GB/GB]; Hope Cottage, Sunnyway, Old Bosham, West Sussex PO18 8HQ (GB). POLLARD-KNIGHT, Denise, Vera [GB/GB]; 4 Drury Road, Harrow, Middlesex HA1 4BY (GB).</p>		
<p>(74) Agent: PENNANT, Pyers; Stevens, Hewlett & Perkins, 5 Quality Court, Chancery Lane, London WC2A 1HZ (GB).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		
<p>(54) Title: ASSAY METHOD USING SURFACE PLASMON RESONANCE SPECTROMETRY</p> <div style="text-align: center; margin: 10px 0;"> <p>Antibody </p> <p>Protein </p> <p>Analyte </p> <p>Analyte analogue </p> </div> <p style="text-align: center;"><u>DISPLACEMENT IMMUNOASSAY</u></p> <div style="display: flex; justify-content: space-around;"> <div style="width: 45%;"> <p>(a) <u>fixed hapten</u></p> </div> <div style="width: 45%;"> <p>(b) <u>fixed antibody</u></p> </div> </div> <p>(57) Abstract</p> <p>In an assay for an analyte, particularly a hapten, changes in refractive index at a solid surface are monitored by means of surface plasmon resonance spectroscopy. The signal is enhanced by conjugating to an assay reagent a substance capable of giving a strong signal. One example is an enzyme used to catalyse production of an insoluble product. Another example is latex beads. Assay formats include sandwich assay format, and a competition assay format preferably involving displacement of the conjugate.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

ASSAY METHOD USING SURFACE
PLASMON RESONANCE SPECTROMETRY

5

This invention concerns methods of assaying for analytes using the technique of surface plasmon resonance spectrometry (SPRS). The method is applicable to analytes generally, but is likely to be of particular interest where the analyte is a hapten (a small molecule capable of being bound by antibody but not of itself immunogenic).

The phenomenon on SPR is well known and will not be described in detail. Two effects are known to give rise to SPR, the Woods effect which involves a metallized diffraction grating; and the Kretschmann effect with which this invention is concerned. Reference is directed to EPA 305109 for a discussion of the Kretschmann effect. Briefly, the intensity of monochromatic plane-polarised light (conveniently obtained from a laser) reflected from the interface between an optically transparent material, e.g. glass, and a thin film of metal depends on the refractive index of material in a thin layer, at most a few hundred nm thick, on the downstream side of the metal. Accordingly, by measuring changes in intensity of reflected light an indication can be obtained of changes in refractive index of material on the metal. The intensity of reflected light also varies with the angle of incidence, and reflectivity drops sharply to a minimum at a particular angle characteristic of the equipment. The metal surface is generally of silver, although this is not critical to the invention.

The immunoassay of haptens by Surface Plasmon Resonance Spectrometry (SPRS) poses a particular problem because the haptens are necessarily of low

- 2 -

molecular weight and therefore cause only very small changes in refractive index when they bind to or dissociate from an antibody-coated SPRS silver-coated surface. This problem is addressed in International
5 Application PCT/GB89/00156.

Two ways around this problem are illustrated in Figure 1 of the attached drawings. In 1 (a), the hapten 10 or analogue is immobilised to the silver surface 12 used for SPRS detection, and binds the
10 corresponding antibody 14. Introduction of free hapten 16 (whose concentration it is wished to determine) displaces antibody by competing with surface bound hapten. This displacement of antibody from the surface is detected as an SPRS signal. In 1 (b), the antibody
15 14 is bound to the surface 12 and binds a conjugate 18 of the hapten 10 or analogue and (typically) a protein 20 of sufficient molecular weight to yield a significant SPRS signal on displacement of the conjugate by added free hapten.

20 However, this arrangement is not always very sensitive. This invention provides a way of increasing the sensitivity.

EPA 276142 describes an SPR assay in which an assay reagent X is chosen to have a high refractive
25 index so as to enhance an SPR signal. In the system described, deposition of the reagent X is monitored by SPR making use of the Woods effect.

The present invention provides a method of assaying for an analyte which is a member of a specific
30 binding pair, by the use of a solid surface carrying immobilised thereon a first reagent which is a member of the specific binding pair, and of a second reagent which is a conjugate of a member of the specific binding pair, at least one of the first and second
35

- 3 -

reagents being a specific binding partner of the analyte,

which method comprises incubating a fluid sample containing the analyte with the first and second reagents simultaneously or in any desired order, whereby the conjugate is caused to be present on the solid surface in a manner related to the presence of the analyte in the sample,

characterised in that there is used as the solid surface a metallic layer applied to a block of material transparent to electromagnetic radiation, the presence of the conjugate on the surface is assayed by surface plasmon resonance spectrometry, and the conjugate is selected to be capable of giving a strong SPR signal.

In one embodiment, either (a) the first reagent is an analogue of the analyte and the second reagent is a conjugate of a specific binding partner of the analyte, or (b) the first reagent is a specific binding partner of the analyte and the second reagent is a conjugate of an analogue of the analyte,

and the assay is performed by effecting competition between the analyte and the analyte analogue for binding with the specific binding partner of the analyte, whereby the conjugate is caused to be present on the solid surface in a manner related to the presence of the analyte in the sample.

An analogue of the analyte is a substance which competes with the analyte for binding to a specific binder therefor. Often the analogue will be arranged to be as near as possible or even completely identical to the analyte. The use in assays of analyte analogues is well known.

In a preferred arrangement, the second reagent is reversibly bound to the first reagent as a preliminary step. When the sample is brought into

- 4 -

contact with the solid surface, competition between the analyte and the analyte analogue causes displacement of a proportion of the second reagent from the detection surface, that proportion being directly related to the concentration of the analyte in the sample. Because that second reagent is a conjugate selected to be capable of giving a strong SPR signal, its displacement from the solid surface is readily and accurately monitored by means of SPRS. An advantage of this arrangement is that the assay is performed simply by bringing the sample into contact with the solid surface, no other reagent being required.

Two embodiments of the invention have been designated (a) and (b). In (a), the first reagent immobilised on the solid surface is an analogue of the analyte, preferably the analyte itself carried on a suitable spacer molecule (generally a macromolecule such as a protein). The second reagent is a conjugate of a specific binding partner of the analyte, most usually of an antibody to the analyte.

In (b) the first reagent, immobilised on the solid surface, is a specific binding partner of the analyte, generally an antibody to the analyte. The second reagent is then a conjugate of a the analyte or of an analogue of the analyte.

In one approach, the second reagent is a conjugate with a substance which itself gives a strong SPR signal, as described below.

In another approach, the second reagent is a conjugate with a member of a different specific binding pair which is non-reactive with the analyte. In this case, the assay includes an additional step of bringing into contact with the solid surface a complex of the other member of the different specific binding pair with a substance which itself gives a strong SPR signal. Examples of the different specific pairs

- 5 -

include the biotin-avidin and biotin-streptavidin systems. Preferably biotin is present in the second reagent.

5 This additional step is performed during or after the competition step of the assay. The complex may be present in a fluid which is brought into contact with the solid surface. Or the complex may be incorporated in the fluid sample. For example the fluid sample may be caused to flow successively over
10 two solid surfaces, of which the first carries the complex in soluble form and the second is the SPR detection surface.

The substance may be one having a high refractive index. This may be a molecule or particle
15 with a high refractive index or a large size, to confer a higher refractive index on the reagent as a whole thus giving rise to a larger SPR signal than would be the case with an unmodified molecule. Possible substances include heavy substances (e.g. metal ions or
20 higher halogens) highly electronically delocalised species (e.g. polycyclic aromatics or dyes), metal or metal oxide particles such as titania particles, or high refractive index organic species such as ferritin.

Alternatively, the substance may be one
25 having a low refractive index, i.e. a refractive index lower than that of the environment close to the solid surface.

Alternatively, the substance may be an enzyme which is caused to catalyse a reaction resulting in the
30 production of a reaction product which is deposited on the solid surface. It is necessary that the reaction product resulting from the action of the enzyme be immobilised on or exceedingly close (i.e. within a thin layer of a few hundred nanometers or less) to the metal
35 surface. The reaction product may have a refractive index which is higher or lower than the material

- 6 -

present in that thin layer. Examples of suitable enzymes are:-

- a) Peroxidase, with H_2O_2 and diamino-benzidine (DAB) as substrates. The latter is converted to an insoluble product.
- b) Certain oxidoreductases with NAD(P)H and a tetrazolium salt as substrate. The latter is converted to an insoluble product (a formazan). Other reductant and dye combinations exist. (See F P Altmann, 1972, "An introduction to the use of tetrazolium salts in quantitative enzyme cytochemistry" published by Koch-Light Laboratories, Colnbrook, Bucks, England).
- c) Certain catalase enzymes are known to generate gas, bubbles of which can be retained close to the solid surface.

When the second reagent is a conjugate of a member of the specific binding pair with an enzyme, the assay may conveniently be performed in a sandwich assay format. In this case, both the first and second reagents are specific binding partners of the analyte (i.e. antibodies when the analyte is an antigen or hapten). This is in contrast to the displacement assays described above which are necessarily performed in a competition assay format.

The assay performed by the method may be qualitative, i.e. simply to detect the presence or absence of an analyte in a sample, or quantitative. For quantitative assays, measurements may be made of the rate of change of reflectivity, and/or of the absolute reflectivity at a given time. Contact between the fluid medium and the solid surface may be static, but is more preferably dynamic e.g. by the fluid medium being caused to flow across the metal surface.

The nature of the analyte is not critical.

- 7 -

However, for the reasons given above, the invention is of particular value when the analyte is a hapten. The first reagent may be immobilised on the surface of the metal e.g. silver layer by conventional means, e.g. covalent bonding or simply physical adsorption. A biotinylated reagent may be immobilised on a metal surface to which streptavidin has been bound. Indeed immobilisation may involve any binding pair, including DNA/DNA or antibody/antigen.

Reference is directed to Figures II, III and IV of the accompanying drawings which illustrate aspects of the invention, and in which:

Figure II comprises two reaction diagrams illustrating one embodiment;

Figure III is a reaction diagram illustrating another embodiment, and

Figure IV shows the final state of the solid surface when an enzyme is used.

Figure II (a) shows the preliminary step in an assay for an analyte in a sample. At the outset, an analogue 22 of the analyte is irreversibly attached to a silver layer 28, and an antibody conjugate 24 is reversibly bound to the analogue.

Figure II (b) shows a similar arrangement. At the outset, antibody 26 to the analyte is irreversibly attached to the silver layer 28 and an analyte analogue conjugate 30 is reversibly bound to the antibody.

Both systems operate in the same way. On addition of a sample 32 containing the analyte 34, a proportion of the conjugate molecules is displaced from the silver layer, that proportion being directly related to the concentration of the analyte in the sample.

Figure III shows a two-step assay. At the start, antibody 36 to the analyte is irreversibly

- 8 -

attached to a silver layer 38, and a conjugate of an analyte analogue 40 with biotin 42 is reversibly bound to the antibody. On addition of a sample 44 containing an analyte 46, a proportion of the conjugate molecules is displaced from the silver layer, that proportion being directly related to the concentration of the analyte in the sample.

A fluid 48 containing a complex of streptavidin 50 with HRP enzyme 52 is then brought into contact with the silver layer. The streptavidin binds to the biotin to an extent inversely related to the concentration of the analyte in the sample.

The final step of the assay is shown in Figure IV. When diamino-benzidine (DAB) and hydrogen peroxide (H_2O_2) are brought into contact with the silver layer, the HRP enzyme catalyses reaction between them leading to formation of an insoluble product which accumulates adjacent the silver layer 38 and gives rise to a strong SPR signal which is easily monitored.

In place of the HRP enzyme 52, there could have been used a high refractive index substance, such as ferritin or a titania particle, as described above.

In another embodiment, an enzyme may be irreversibly bound on the solid surface in an inactive form. When the fluid sample is brought into contact with the solid surface, analyte in the sample may activate the enzyme which may then be used to generate an SPR signal in the manner shown in Figure 4. The enzyme thus activated by the analyte may itself be one which generates an insoluble product; or may be one which generates a substrate for such an enzyme.

The following Examples illustrate the invention

In each of Examples 1 and 2, the analyte is human immunoglobulin, and a sandwich assay format is used. The first reagent, immobilised on a silver

- 9 -

surface, is an anti-human immunoglobulin antibody. The second reagent is an (anti-human immunoglobulin antibody) - enzyme conjugate. In a first step, a sample containing the analyte is brought into contact with the silver surface, whereby the analyte binds to the immobilised first reagent (present in excess).

In a second step, a solution of the second reagent is brought into contact with the silver surface, whereby the second reagent becomes bound on the solid surface to an extent proportional to the amount of analyte in the sample. This gives rise to a small but measurable SPRS signal. To amplify the signal, a substrate for the enzyme is supplied to cause an insoluble reaction product to be deposited on the silver surface.

In Examples 1 and 2, the first step is assumed to have taken place, and the second step is performed by applying the second reagent direct to the silver surface. The second step, demonstrated in the Examples, is the key to the method.

Example 1

An anti-human immunoglobulin- β galactosidase conjugate was diluted to 36nM in 10mM sodium phosphate pH 7.4 and 1ml pumped across a silver slide at 8 μ l/sec. The shift in the angle at which SPR occurs (change in reflectivity) was monitored on binding the conjugate. 3mls of 10mM sodium phosphate pH7.4 was then manually injected across the slide to wash the surface.

A block of sheep immunoglobulin (2 μ M, 1ml) in 10mM sodium phosphate pH7.4 3mM MgCl₂, was injected across the slide, followed by a wash of 3mls of 10mM sodium phosphate pH7.4, 3mM MgCl₂, 0.5% BSA. The substrate solution (VLM from PPR Diagnostics, Kings College, London) diluted to 0.4mM in 10mM phosphate

- 10 -

buffer pH7.4 was then flowed at 3 μ l/sec across the slide and the change in reflectivity monitored with time. A wash step of 3mls of 10mM sodium phosphate was then performed.

5 The results from two experiments are shown in the table below. There is at least a five fold enhancement of the signal on addition of the substrate.

Example 2

10

 An anti-human immunoglobulin-alkaline phosphatase conjugate diluted to 0.125nM and 60pM in 10mM Tris/HCl pH 9.5, 3mM MgCl₂ (dilution buffer) was flowed across a silver coated slide at 4 μ l/sec and the
15 change in reflectivity monitored. Following a wash step with 3mls of this same buffer, the slide was blocked with 2 μ M sheep immunoglobulin in 10mM Tris/HCl pH 9.5, 3mM MgCl₂ (1ml manual injection). A further wash step (3mls of dilution buffer) was performed and
20 the enzyme substrate solution (3.3mg/ml nitro-blue tetrazolium, 1.65mg/ml 5-bromo-4-chloro-3-indoyl-phosphate in dilution buffer) then flowed across the slide at 3 μ l/sec. The change in reflectivity with time was monitored.

25 The table below shows the results for 0.125nM and 60pM anti-human immunoglobulin-alkaline phosphatase conjugate respectively. The addition of the enzyme substrate significantly enhances the sensitivity of the
30 assay.

35

35

- 11 -

Final Change in Reflectivity (%)

	Bind of enzyme conjugate	Addition of enzyme substrate	
5			
	Example 1		
	36nM β -galactosidase-	7	37
10	anti-human immunoglobulin		
	Example 2		
	0.125nM anti-human		
	immunoglobulin	4	51
15	-alkaline phosphatase		
	60 pM anti-human		
	immunoglobulin	2.2	28
20	-alkaline phosphate		

Example 3

25 A Displacement Assay for Human Chorionic Gonadotrophin (HCG) using a Refractive Index Probe

10mM sodium phosphate buffer, pH 7.4 (buffer 1) was pumped across the silver slide and the change in SPR angle monitored. A solution of 166nM human

30 immunoglobulin-HCG conjugate diluted in buffer 1 was then bound to the silver surface by pumping across the surface at 8 μ l/sec. Following a wash step with buffer 1, the silver surface was then blocked by manual

35 injection of 2 μ M sheep immunoglobulin diluted in 10mM sodium phosphate buffer, pH7.4 containing 0.5% bovine serum albumin (buffer 2) across the silver slide. A

- 12 -

mouse anti-HCG monoclonal antibody, free in solution or linked onto 55nm polystyrene refractive index probes (enhanced sensitivity), was then bound to the previously immobilised HCG-conjugate by pumping a 100nM solution of the anti-HCG antibody diluted in buffer 2 across the silver slide. The silver slide was then washed with buffer 2. 1µM HCG diluted in buffer 2 was then added and displacement of the anti-HCG antibody from the silver surface was observed by SPR. As shown in the table below both the rate of displacement and the final change in the shift in the SPR angle were greater when the anti-HCG antibody was attached to the 55nm polystyrene refractive index probes.

	DISPLACED MOLECULE	
	Anti-HCG antibody immobilised on refractive index probe	Anti-HCG antibody
SPR Parameter		
RATE*	-0.0322	-0.0043
FINAL CHANGE**	-7.4%	-1.2%
* change in reflectivity per second		
** change in reflectivity at the end of the assay		

CLAIMS

5

1. A method of assaying for an analyte which is a member of a specific binding pair, by the use of a solid surface carrying immobilised thereon a first reagent which is a member of the specific binding pair,
10 and of a second reagent which is a conjugate of a member of the specific binding pair, at least one of the first and second reagents being a specific binding partner of the analyte,

which method comprises incubating a fluid
15 sample containing the analyte with the first and second reagents simultaneously or in any desired order, whereby the conjugate is caused to be present on the solid surface in a manner related to the presence of the analyte in the sample,

20 characterised in that there is used as the solid surface a metallic layer applied to a block of material transparent to electromagnetic radiation, the presence of the conjugate on the surface is assayed by surface plasmon resonance spectrometry, and the
25 conjugate is selected to be capable of giving a strong SPR signal.

2. A method as claimed in claim 1, wherein either a) the first reagent is an analogue of the analyte and the second reagent is a conjugate of a
30 specific binding partner of the analyte, or b) the first reagent is a specific binding partner of the analyte and the second reagent is a conjugate of an analogue of the analyte, and the incubation step is performed so as to effect competition between the
35 analyte and the analyte analogue for binding with the specific binding partner of the analyte.

- 14 -

3. A method as claimed in claim 1 or claim 2, wherein the conjugate is with a substance which gives a strong SPR signal.

5 4. A method as claimed in claim 1 or claim 2, wherein the conjugate is with a member of a different specific binding pair which is non-reactive with the analyte, and the assay includes the additional step of bringing into contact with the solid surface a complex
10 of the other member of the different specific binding pair with the substance which gives a strong SPR signal.

5. A method as claimed in claim 3 or claim 4, wherein the substance is one having a high refractive index.

15 6. A method as claimed in claim 1 or claim 2, wherein the second reagent is a conjugate of a member of the specific binding pair with an enzyme, which enzyme is caused to catalyse a reaction resulting in the production of a reaction product which is deposited
20 on the solid surface.

7. A method as claimed in any one of claims 1 to 6, wherein the second reagent is reversibly bound to the first reagent and the sample is then brought into contact with the solid surface, whereby a proportion of
25 the second reagent, directly related to the concentration of the analyte in the sample, is displaced from the detection surface.


8. A method as claimed in claim 6, wherein a sandwich assay format is used.

30 9. A method as claimed in any one of claims 1 to 8, wherein the analyte is a hapten.

1/4



FIG. 1 DISPLACEMENT IMMUNOASSAY








FIG. II DISPLACEMENT IMMUNOASSAY



3/4



Antibody




Analyte

Conjugate of biotin
and
analyte
analogueConjugate of enzyme
and
streptavidin

4/4

FIG. IV



INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/00433

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : G 01 N 33/543, G 01 N 21/75																										
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> Classification System: Classification Symbols IPC ⁵ G 01 N 33/553, 33/543, 21/75, 21/55 <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸</div>																										
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; width: 10%;">Category ¹⁰</th> <th style="text-align: left; width: 70%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="text-align: left; width: 20%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="vertical-align: top;">A</td> <td style="vertical-align: top;">EP, A, 0276142 (ARES SERONO RESEARCH) 27 July 1988 see page 1, line 33; page 2; page 3, to line 60; page 5, line 20; page 6, to line 26 (cited in the application)</td> <td style="vertical-align: top; text-align: center;">1</td> </tr> <tr> <td colspan="3" style="text-align: center;">--</td> </tr> <tr> <td style="vertical-align: top;">A</td> <td style="vertical-align: top;">EP, A, 0305109 (AMERSHAM INT. PLC) 1 March 1989 see column 3, line 40; column 4; column 5, to line 15 (cited in the application)</td> <td style="vertical-align: top; text-align: center;">1</td> </tr> <tr> <td colspan="3" style="text-align: center;">--</td> </tr> <tr> <td style="vertical-align: top;">A</td> <td style="vertical-align: top;">Analytical Chemistry, volume 56, no. 8, July 1984, American Chemical Society, D. Monroe: "Enzyme Immunoassay", pages 920(A)-931(A) see pages 921(A); 922(A); 924(A), down to "unbound";</td> <td style="vertical-align: top; text-align: center;">1</td> </tr> <tr> <td colspan="3" style="text-align: center;">--</td> </tr> <tr> <td colspan="3" style="text-align: right;">./.</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A, 0276142 (ARES SERONO RESEARCH) 27 July 1988 see page 1, line 33; page 2; page 3, to line 60; page 5, line 20; page 6, to line 26 (cited in the application)	1	--			A	EP, A, 0305109 (AMERSHAM INT. PLC) 1 March 1989 see column 3, line 40; column 4; column 5, to line 15 (cited in the application)	1	--			A	Analytical Chemistry, volume 56, no. 8, July 1984, American Chemical Society, D. Monroe: "Enzyme Immunoassay", pages 920(A)-931(A) see pages 921(A); 922(A); 924(A), down to "unbound";	1	--			./.		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																								
A	EP, A, 0276142 (ARES SERONO RESEARCH) 27 July 1988 see page 1, line 33; page 2; page 3, to line 60; page 5, line 20; page 6, to line 26 (cited in the application)	1																								
--																										
A	EP, A, 0305109 (AMERSHAM INT. PLC) 1 March 1989 see column 3, line 40; column 4; column 5, to line 15 (cited in the application)	1																								
--																										
A	Analytical Chemistry, volume 56, no. 8, July 1984, American Chemical Society, D. Monroe: "Enzyme Immunoassay", pages 920(A)-931(A) see pages 921(A); 922(A); 924(A), down to "unbound";	1																								
--																										
./.																										
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																										
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">4th June 1990</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">27 JUL 1990</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;"> Mme N. KUIPER </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">4th June 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center;">27 JUL 1990</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> Mme N. KUIPER </div>																				
Date of the Actual Completion of the International Search <div style="text-align: center;">4th June 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center;">27 JUL 1990</div>																									
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> Mme N. KUIPER </div>																									

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP, A, 0028132 (DYNASCIENCES CORP.) 6 May 1981 see page 3, first paragraph; page 5, down to "dinitrobenzenes" -----	1

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9000433

SA 35707

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/07/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0276142	27-07-88	AU-A- 1063188	28-07-88
		JP-A- 63271162	09-11-88
EP-A- 0305109	01-03-89	AU-A- 2110988	23-02-89
		JP-A- 1138443	31-05-89
EP-A- 0028132	06-05-81	AU-B- 533026	27-10-83
		AU-A- 6295280	30-04-81
		CA-A- 1146853	24-05-83
		JP-A- 56071023	13-06-81
		US-A- 4410634	18-10-83

ETO FORM 10479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82